Entero Therapeutics Inc (ENTO)
$0.82
Performance
- $0.75$1.03$0.82
8.54%
Downside
Day's Volatility :26.83%
Upside
20.0%
- $0.82$22.20$0.82
0.0%
Downside
52 Weeks Volatility :96.31%
Upside
96.31%
Returns
| Period | Entero Therapeutics Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -67.18% | 0.0% |
6 Months | -67.18% | 0.0% |
1 Year | -67.18% | 0.0% |
3 Years | -67.18% | -20.2% |
Highlights
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | 0.0% |
Return On Equity TTM | 0.0% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
Diluted Eps TTM | 0.0 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
Analyst Recommendation
Technicals Summary
Sell
Neutral
Buy
Entero Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Entero Therapeutics Inc | -43.14% | -67.18% | -67.18% | -67.18% | -67.18% |
 Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
 Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
 Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
 Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Entero Therapeutics Inc | NA | NA | NA | 0.0 | 0.0 | 0.0 | NA | NA |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Entero Therapeutics Inc | NA | $2.5M | -67.18% | NA | 0.0% |
Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Company Information
azurrx biopharma aims to become a leader in developing non-systemic, recombinant protein therapies for the treatment of gastrointestinal diseases and related conditions. ms1819 recombinant lipase for exocrine pancreatic insufficiency is the lead development program with additional early stage research being conducted for the prevention of hospital-acquired infection. the company is headquartered in new york, ny, with scientific operations based in langlade, france.
Organization | Entero Therapeutics Inc |
Employees | 9 |
CEO | James Sapirstein |
Industry | Miscellaneous |
Discover More
A Spac I Acquisition Corp
$0.82
-16.16%
Keyarch Acquisition Corp
$0.82
-16.16%
Connexa Sports Technologies Inc
$0.82
-16.16%
Us Value Etf
$0.82
-16.16%
First Wave Biopharma Inc
$0.82
-16.16%
Global X Msci Next Emerging
$0.82
-16.16%
Fat Projects Acquisition Corp
$0.82
-16.16%
Capital Link Global Fintech
$0.82
-16.16%
Applied Uv Inc
$0.82
-16.16%